Abstract:Background Ghrelin ( GHRL ) is a pivotal peptide regulator of food intake, energy balance, and body mass. Weight gain (WG) is a common side effect of the atypical antipsychotics (AAPs) used to treat schizophrenia (SZ). Ghrelin polymorphisms have been associated with pathogenic variations in plasma lipid concentrations, blood pressure, plasma glucose, and body mass index (BMI). However, it is unclear whether GHRL polymorphisms are associated with WG due to AAPs. Furthermore, there is no evidence of an association between GHRL polymorphisms and SZ or the therapeutic response to AAPs. We explored these potential associations by genotyping GHRL alleles in SZ patients and controls. We also examined the relation between these SNPs and changes in metabolic indices during AAP treatment in SZ subgroups distinguished by high or low therapeutic response. Methods Four SNPs (Leu72Met, -501A/C, -604 G/A, and -1062 G > C) were genotyped in 634 schizophrenia patients and 606 control subjects. Results There were no significant differences in allele frequencies, genotype distributions, or the distributions of two SNP haplotypes between SZ patients and healthy controls ( P > 0.05). There was also no significant difference in symptom reduction between genotypes after 8 weeks of AAP treatment as measured by positive and negative symptom scale scores (PANSS). However, the -604 G/A polymorphism was associated with a greater BMI increase in response to AAP administration in both APP responders and non-responders as distinguished by PANSS score reduction ( P < 0.001). There were also significant differences in WG when the responder group was further subdivided according to the specific AAP prescribed ( P < 0.05). Conclusions These four GHRL gene SNPs were not associated with SZ in this Chinese Han population. The -604 G/A polymorphism was associated with significant BW and BMI increases during AAP treatment. Patients exhibiting higher WG showed greater improvements in positive and negative symptoms than patients exhibiting lower weight gain or weight loss.

[No Association of -1438G/A Polymorphism in Promoter Region of 5-HT2A Receptor Gene with Antipsychotic Agent-Induced Weight Gain].

[Association of -2548G/A Functional Polymorphism in the Promoter Region of Leptin Gene with Antipsychotic Agent-Induced Weight Gain].

No association of antipsychotic agent-induced weight gain with a DA receptor gene polymorphism and therapeutic response.

Relationship of Antipsychotic Drug-Induced Weight Gain with the Polymorphism of Dopamine D2 Receptor Gene and Treatment Response in Schizophrenic Patients

Genome-Wide Association Study Suggested Theptprdpolymorphisms Were Associated with Weight Gain Effects of Atypical Antipsychotic Medications

Association of A2BP1 Gene Polymorphism with Olanzapine Induced Bodyweight Gain

Common promoter variants of the NDUFV2 gene do not confer susceptibility to schizophrenia in Han Chinese

Significant Linkage and Association Between a Functional (gt)n Polymorphism in Promoter of the N-methyl-D-aspartate Receptor Subunit Gene (GRIN2A) and Schizophrenia.

Leptin -2548G/a Gene Polymorphism in Association with Antipsychotic-Induced Weight Gain: a Meta-Analysis Study.

Association between Ghrelin gene (GHRL) polymorphisms and clinical response to atypical antipsychotic drugs in Han Chinese schizophrenia patients

A Pharmacogenomic Study Revealed an Association Between SLC6A4 and Risperidone-Induced Weight Gain in Chinese Han Population.

A2BP1 Gene Polymorphisms Association with Olanzapine-Induced Weight Gain.

Association of <i>MTHFR</i> C677T Polymorphism With Antipsychotic-Induced Change of Weight and Metabolism Index

TOX and ADIPOQ Gene Polymorphisms Are Associated with Antipsychotic-Induced Weight Gain in Han Chinese

Association study of FTOgene polymorphism with weight gain associated with 4 week risperidone treatment

Pharmacogenetics of Treatment in First-Episode Schizophrenia: D3 and 5-HT2C Receptor Polymorphisms Separately Associate with Positive and Negative Symptom Response

Association of MTHFR C677T polymorphism with weight gain induced by risperidone in schizophrenia

Association Between A-241G Polymorphism of Dopamine D2 Receptor Promoter Gene and Schizophrenia in Chinese

Association Between a Polymorphism of the HTR3A Gene and Therapeutic Response to Risperidone Treatment in Drug-Naive Chinese Schizophrenia Patients

C677T Polymorphism in the MTHFR Gene is Associated with Risperidone-Induced Weight Gain in Schizophrenia.

No association between alleles or genotypes at the dopamine transporter gene and schizophrenia.